IMPORTANCE Risk factors for abdominal aortic aneurysm (AAA) are largely unknown, which has hampered the development of nonsurgical treatments to alter the natural history of disease.
A bdominal aortic aneurysm (AAA) is an important cardiovascular disease (CVD) resulting in approximately 4500 deaths from AAA rupture per year in the United States. 1 Approximately 45 000 operations are carried out each year to prevent rupture, resulting in 1400 deaths. 1 Screening for AAA reduces the burden of rupture, 2 and therefore many countries now offer such screening to at-risk groups. 3, 4 The US Preventive Services Task Force recommends screening men aged 65 to 75 years with a history of smoking, and the American Heart Association guidelines suggest surgical repair is needed when the AAA reaches 5.5 cm in diameter.
Abdominal aortic aneurysm shares risk factors with occlusive atherosclerotic disease, but the magnitude and direction of this association is not always consistent. A growing body of evidence suggests considerable heterogeneity of risk factor associations among different forms of CVDs. [5] [6] [7] For example, the risk of smoking for AAA is at least 2-fold greater than that for coronary heart disease (CHD), 7 whereas type 2 diabetes appears to be protective for AAA but is a major risk factor for occlusive vascular disease. 6 This example suggests that AAA may have some distinct causal pathways, and understanding these pathways is important for setting public health policies aimed at reducing the risk posed by AAA and its complications. . Again, these findings lend support to the hypothesis that AAA and CHD have overlapping pathophysiology, but the association with AAA and not with other CVDs suggests that discrete etiological pathways may well exist between these vascular diseases. The role of low-density lipoprotein cholesterol (LDL-C) levels in CHD is well defined, and LDL-C lowering therapies are of clear benefit in reducing CHD risk. 15 Genetic studies appear to support a causal role for hypertriglyceridemia in CHD, [16] [17] [18] but genetic and clinical studies have cast doubt on the status of highdensity lipoprotein cholesterol (HDL-C) as a causal factor in CHD. 16, [18] [19] [20] [21] In AAA, meta-analyses of observational studies do show a consistent inverse association of HDL-C with AAA risk, but the association with LDL-C is less clear. 22, 23 It is important, however, to recognize that the studies included in these metaanalyses were small case-control studies, many of which did not adjust for statin use. There is a paucity of any data reporting an association between triglycerides (TG) and AAA risk or progression. From a clinical point of view, it is important to understand the role of lipids in AAA, especially considering the excess cardiovascular risks in patients with AAA 24 and the recent publications showing low prevalence of lowering levels of LDL-C in patients with AAA. 25, 26 Previous genetic association studies have pointed to a potential role of lipids in AAA pathology, 10, 11, 27 but this current study uses a larger panel of single-nucleotide polymorphisms (SNPs), a considerably larger sample, and more advanced methods.
Mendelian randomization (MR) is an approach that uses the unique properties of genotype to investigate causal associations. 28 Specifically, genotype is randomly allocated at conception (owing to Mendel's second law, a feature that is exploited to minimize confounding) and is not affected by reverse causation. Although MR has traditionally been used to explore causal associations between circulating biomarkers and disease phenotypes, it has an extension that uses genotype to validate drug targets. In this approach, variants in genes encoding potential drug targets are used as instruments to explore the utility of targeting this pathway in specific disease states. 29 the Netherlands, and Iceland. 9 The GRS were composed of SNPs that are robustly associated with serum lipids in the Global Lipids Genetics Consortium meta-GWAS of circulating lipid levels. 33 Data collection for this study took place between January 9, 2015, and January 4, 2016. Data analysis was conducted between January 4, 2015, and December 31, 2016.
Study Populations
We used summary SNP-AAA association statistics from the 5 published GWASs of AAA. Detailed descriptions of these GWAS
Key Points
Question What is the association between genetically elevated lipid levels and the risk for abdominal aortic aneurysm?
Findings In this meta-analysis of up to 4914 cases and 48 002 controls in 5 genome-wide association studies, genetic elevation of low-density lipoprotein cholesterol and triglyceride levels were associated with an elevated risk of abdominal aortic aneurysm and high-density lipoprotein cholesterol level was associated with a lower risk of abdominal aortic aneurysm.
Meaning Patients with abdominal aortic aneurysm have a high burden of genetically determined dyslipidemia; targeting lipids in this high-risk group may improve longer-term outcomes.
analyses are provided in the eAppendix in the Supplement and previous publications. 9,13,14 We supplemented the study of single variants in genes encoding lipid drug targets with data derived from the Secondary Manifestations of Arterial Diseases (SMART) study. The Table includes the number of cases and controls in each study. Descriptions of study cohorts and demographic details are presented in the eAppendix in the Supplement and previous publications. 9, 13, 14 In all studies, the case definition of AAA was an infrarenal aortic diameter of 3 cm or more by ultrasound or computed tomographic imaging or previous AAA rupture or repair. Details of the association tests and quality control used in each study are included in the eAppendix in the Supplement and a published meta-GWAS.
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Selection of SNPs
We identified SNPs associated with lipids in the Global Lipid Genetics Consortium 33 using the SNP selection criteria by Do et al. 16 Briefly, SNPs in association with at least 1 of the 3 lipid traits (LDL-C, HDL-C, or TG concentrations) at a genome-wide significance level (P <5×10 
Data Analysis
We first harmonized SNPs across the data sets (Global Lipids Genetics Consortium and Aneurysm Consortium) by merging SNPs on the reference SNP cluster identification or rs number. Then, we ensured that effect alleles were denoted to be the same in both data sets and double-checked the information by investigating effect-allele frequencies. We oriented all variants to ensure that the effect allele was positively associated with each lipid trait (eg, in the MR of LDL-C, all β coefficients for LDL-C were >0). This orientation resulted in a data set in which each SNP was a unique row and there were separate columns for β and SEs for each lipid trait and the log odds ratio (OR) and corresponding SE for AAA (eTable 1 in the Supplement).
Conventional MR
We conducted a conventional 2-sample MR analysis to determine the association between a 1-SD genetically elevated lipid concentration and AAA risk. For this analysis, we used the inverse-variance weighted MR method in which the SNP association estimates for the outcome (β for AAA) are regressed on the SNP association estimates for each lipid (β for LDL-C, β for HDL-C, and β for TG) individually in turn. The regression was weighted by the inverse variances of the estimated associations of the SNPs with the outcome and then was forced to pass through the origin.
Multivariable MR
To gauge some insight into potential "independent" associations of the lipids with AAA risk, we used the multivariable MR method. In this approach, a single regression model with outcome variable (β for AAA) was fitted for the predictor variables (β for LDL-C, β for HDL-C, and β for TG). The model was implemented, as described previously, 34 as a multilinear regression of SNP association estimates weighted by the inverse variances of the estimated associations of SNPs with the outcome and forced to pass through the origin.
MR-Egger
We used the MR-Egger 32 method that tests for the presence of, and provides an MR estimate that is adjusted for, unmeasured net pleiotropy. The method involves conducting an unconstrained linear regression of the SNP association estimates for the outcome on the SNP association estimates for the exposure weighted by the inverse variance of the estimated association of SNP with outcome. In MR-Egger, any net pleiotropy manifests in the intercept. Under the assumption that pleiotropic associations are independent of the associations of the SNPs with the exposure, the regression slope coefficient should represent an unbiased MR association estimate.
Weighted Median MR
As a further sensitivity analysis, we performed the weighted median MR method. 31 Whereas the conventional inversevariance weighted method calculates a weighted mean of the SNP-specific causal association estimates, the weighted median method calculates a weighted version of the median of the SNP-specific causal association estimates. Because the median of a distribution is not affected by extreme values, the weighted median method is less sensitive to individual pleiotropic SNPs. The weighted median estimate is unbiased in large samples if at least 50% of the weights from SNPs are valid (eg, not pleiotropic). 
Statistical Calculations
The MR analyses for blood lipids were performed using the "MendelianRandomization" command in R, version 3.3.3 (R Foundation for Statistical Computing), 35 and 2-tailed P values were derived from instrumental variable estimators. Given that there was only one outcome under investigation (AAA) and the lipids traits were correlated with one another, we used 2-tailed P < .05 to denote evidence against the null hypothesis (ie, P < .05 provided evidence in favor of an association between the exposure and outcome).
Results
The numbers of cases and controls for each of the 5 AAA GWASs are shown in the ) and rs646776 in SORT1 (OR per allele, 0.88; 95% CI, 0.82-0.94; P =3. 9×10 ). Twenty-five of 180 SNPs (13.8%) were nominally associated with AAA (P < .05; eTable 2 in the Supplement) with 9 such associations (95% CI, 4-15) being expected by chance alone.
We conducted conventional inverse-variance weighted MR analyses using GRS for LDL-C (75 SNPs), HDL-C (84 SNPs), and TG levels (50 SNPs) to assess the associations with AAA ( Figure 1 ). The LDL-GRS was strongly associated with AAA risk (OR per SD higher level for LDL-C, 1.66; 95% CI, 1.41-1.96;
). A 1-SD higher HDL-C level instrumented through the HDL-C GRS was associated with a reduced AAA risk (OR, 0.67; 95% CI, 0.55-0.82; P =8.3×10 −5 ). In addition, the TG-GRS was associated with higher AAA risk (OR per 1-SD higher TG level, 1.69; 95% CI, 1.38-2.07; P =5.2×10 −7
).
Multivariable MR, MR-Egger, and Weighted Median MR Approaches
It is possible to remove SNPs with pleiotropic associations from the GRS, but this removal diminishes the strength of the instrumental variable 36 and can introduce bias. 37 Therefore, we adopted the multivariable MR method described by Do et al 16 and modified by Burgess and Thompson 34 to gain insight into the potential independent associations of these lipid GRS with AAA risk. To account for any net unbalanced pleiotropy, we used the MR-Egger method. To reduce the influence of outlying (possibly pleiotropic) variants on the analysis, we used the weighted median MR method. None of these sensitivity MR analyses resulted in a material change to either the magnitude or significance of the estimates ( Figure 1 ). The point estimates for concentrations of LDL-C and HDL-C remained largely unaltered, whereas for TG the point estimate diminished for the multivariable MR method; however, on the MR-Egger and weighted median MR methods, TG level remained convincingly associated with AAA. 
Association of SNPs With Lipid Drug Targets
We selected rs12916 in HMGCR, rs3764261 in CETP, as well as rs2479409 and rs11206510 in PCSK9 as there are licensed drugs that target pathways associated with these genes.
The LDL-C-lowering allele of rs12916 (to proxy statin use) was associated with a lower AAA risk in meta-analysis (OR per LDL-C-lowering allele, 0.93; 95% CI, 0.89-0.98; P = .009) ( Figure 2) .
The PCSK9 inhibitors are a novel class of drugs used to target LDL-C. To date, in CHD, genetic and clinical studies have had concordant results.
33, 38 We examined 2 independent SNPs in PCSK9 (rs2479409 and rs11206510; linkage disequilibrium r 2 = 0.07) that were used as proxies for PCSK9 inhibition in a large-scale MR analysis 39 and have strong, independent associations with both LDL-C levels and CHD. The LDL-C-lowering allele of rs2479409 was not associated with AAA risk (OR, 0.97; 95% CI, 0.92-1.02; P = .28). The LDL-C-lowering allele of rs11206510 in PCSK9 was weakly associated with AAA risk (OR, 0.94; 95% CI, 0.88-1.00; P =.04) ( Figure 2 ). We used rs3764261 as a proxy for CETP inhibition. Although the allele increases HDL-C levels, it is also associated with lower circulating concentrations of TG and LDL-C; thus, rs3764261 cannot be considered as an instrument for HDL-C in isolation but can be used to gauge insight into the potential associations with CETP inhibition. 30 This HDLraising CETP SNP was associated with lower AAA risk (OR per HDL-C-raising allele, 0.89; 95% CI, 0.85-0.94; P =3. 7×10 −7 ).
Discussion
Understanding the relevance of lipid fractions in the development of AAA has important implications from both etiological and translational standpoints. In this study, we used MR to provide robust evidence that the major lipid fractions-LDL-C, HDL-C, and TG-are likely to play important roles in the etiology of AAA. A similar genetic approach has been used previously, 27 but this present study has expanded on this technique by including many more individuals and more SNPs and by using more recent developments in MR, which collectively increase statistical power and strengthen the validity of the association estimates reported here. Disentangling the roles of correlated biomarkers in disease etiology continues to be an analytical challenge; to this end, we used recently developed techniques for the multivariable MR method. 16 Interestingly, there appear to be independent associations between genetically instrumented levels of LDL-C, HDL-C, and TG and AAA risk. This finding is in contrast to findings in studies of CHD in which a similar approach found weaker associations between HDL-C genetic variants and CHD (after shared pathways with LDL-C and TG and pleiotropy had been taken into account 16,18,19,36 ) or aortic stenosis in which only LDL-C appeared to play a causal role. 40 This finding highlights the complexity of lipid pathways across the diverse biology of CVD and suggests that results from studies focused solely on CHD (which can be defined variably) cannot always be extrapolated to other vascular diseases such as AAA. Although it has been possible to investigate for pleiotropic associations of genetic variants used collectively in the lipid GRS employed in the MR analyses we conducted, it is not so straightforward as to disentangle the phenotypic overlap whereby many patients with AAA also harbor atherosclerotic disease in other vascular beds. Therefore, it is tempting to suggest a causal role for lipids specifically in AAA pathogenesis, but these genetic analyses do not provide definitive evidence. The data do suggest, however, that the burden of genetically influenced dyslipidemia in patients with AAA is considerable, and by extrapolation, these MR analyses lend support to the lipids playing an important role in AAA etiology and thus targeting lipids through pharmacological modification in patients with small AAAs may well be justified. This point is particularly pertinent given the recent reports of low prevalence of control of LDL-C concentrations in patients with AAA in both the United States and the United Kingdom. 25, 26 In addition, this group of patients should be considered in trials evaluating novel treatments of lipid-lowering medications, such as CETP or PCSK9 inhibitors. The use of genetic data to inform drug trials and/or drug repurposing represents an important translational facet of data derived by large genome-wide consortia. 41, 42 In addition to the GRS for LDL-C, HDL-C, and TG, we looked at 4 loci that serve Indeed, there has been a suggestion that statin use may increase AAA risk. 44 The collective results from this study suggest that LDL-C plays an important role in the etiology of AAA, which may explain the excess burden of CVD in patients with AAA. 24 These data also support a view that patients found by screening to have AAA should be prescribed statins to reduce their CVD risk, although whether this will affect the progression of AAA cannot be answered in this study. A recent phase 3 clinical trial showed that PCSK9 inhibitors have beneficial effects on CVD outcomes. 38 Although the association we found between PCSK9 variants and AAA was weak, if PSCK9 inhibitors do prove to be a safe and costeffective means of lowering LDL-C levels, then consideration should be given to evaluating these drugs in patients with AAA.
As noted, a genetically instrumented higher HDL-C level was identified to be associated with a reduction in AAA risk. Variants in CETP have a range of results similar to pharmacological inhibition of CETP, 30 including lowering of LDL-C and raising of HDL-C levels. A trial of CETP inhibition showed modest benefit in patients following myocardial infarction, 45 and there are data to support its beneficial effects on vascular remodeling 46 that could have relevance in AAA management. Evaluation of CETP inhibition in patients with AAA may therefore be warranted. Although we cannot specifically determine whether the association between CETP polymorphisms and AAA is via HDL-C, LDL-C, or TG (or indeed all, as suggested by our GRS of lipid traits), we believe our results suggest that CETP inhibition could play a role in the management of AAA. The findings regarding TG variants also have potential clinical implications for the development of novel treatments aimed at TG levels. They suggest that patients with AAA may benefit from lowering TG levels. As novel therapies such as APOC3 inhibitors progress from phase 2 studies to larger-scale phase 3 studies of CVD prevention, then patients with AAA could be an important CVD subphenotype in whom treatment should be evaluated.
Our study used MR, a genetic approach that has important assumptions. The SNPs used in the genetic instruments for each lipid trait were identified from recent GWASs that placed stringent thresholds on SNP discovery. As such, the genetic instruments are very unlikely to suffer from weak instrument bias; in any case, because the MR analyses used nonoverlapping data sets, such bias would tend to dilute the estimates derived from MR analyses. 47 In addition, we made the assumption that the genetic instruments are not influenced by confounding and that they only associate with AAA through the exposure of interest (ie, the genetic instruments are not affected by unbalanced horizontal pleiotropy, as pictorially illustrated in Figure 1 . These assumptions cannot be tested with complete certainty. However, causal estimates obtained from a range of sensitivity analyses, each making different and weaker assumptions, all gave similar results. Nonetheless, residual pleiotropy could still influence our findings.
Limitations
The limitations of this study should be considered. First, we did not have data sets to evaluate AAA progression. Second, owing to limited availability of covariate data, we were unable to examine the influence of concurrent lipid-lowering therapy on the estimates derived from the GRS for blood lipid traits and AAA risk. Third, our analyses used summary-level data as described elsewhere.
16,48 Use of summary-level data can hamper more refined analyses (eg, subgroup analyses by sex or age), but one of its main strengths is it facilitates 2-sample MR analyses of the type reported here. This greatly strengthens the power of the study, which enables the conduct of sensitivity analyses (such as MR-Egger and weighted median MR methods) and the investigation of certain instrumental variable assumptions such as the absence of genetic pleiotropy. Finally, although we attempted to control for pleiotropy in the analyses, we believe pleiotropy still represents a major challenge to deciphering the roles of specific lipid-based pathways.
Conclusions
Using contemporary MR approaches, we found data that lend support to the hypothesis that major lipid fractions are involved in the etiology of AAA. Consideration should be given to measures aimed at targeting lipids to reduce risk of AAA, using established and emerging therapies. 
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eAppendix. Methods
Cohorts
The GWAS cohorts used in this MS are described in detail in the recent meta analysis of AAA GWAS study
The Aneurysm Consortium
Aneurysm Consortium AC AAA GWAS dataset The AC recruited cases of AAA from centers across the United Kingdom and Western Australia Cases were defined as patients with an infra renal aortic diameter mm proven on ultrasound or computerized tomography CT scan Controls were taken from the Wellcome Trust Case Control Consortium WTCCC common control group and were therefore unscreened for AAA Data from cases with AAA and unscreened controls from the WTCCC study consisting of samples from the British Birth Cohort and from the UK National Blood Service DNA samples were processed at the Wellcome Trust Sanger )nstitute WTS) Genomic DNA was quantified by PicoGreen assay and quality control QC assured by both agarose gel electrophoresis and Sequenom iPLEX genotyping of SNPs and sex specific markers Genotyping for the discovery study was performed using )llumina M controls or K AAA BeadChips
As part of the original AC GWAS individual sample QC had been performed as follows QC was first performed by exclusion of SNPs with call rates and those that demonstrated significant deviation from (ardy Weinberg equilibrium in the control group P x Duplicate samples and those that failed genotyping sample call rates were also excluded from further analysis Genotyping cluster plots for all SNPs with P x were visually inspected to exclude from further analysis positive associations generated by erroneous genotyping or calling Checks for population stratification were performed by PL)NK identical by state clustering and extreme outliers were removed from the analysis )mputation was performed using )MPUTE run on the BC)SNPmax database platform version BC) Platforms Espoo Finland The reference haplotypes were based on the Genomes June release )mputed calls were filtered by quality score excluding those to restrict to higher quality imputed SNPs
Following imputation further QC filtering was performed excluding SNPs with call rates and those that demonstrated significant deviation from (ardy Weinberg equilibrium in the control group P x Duplicate samples and those that failed genotyping sample call rate were also excluded from further analysis Association testing was carried out in PL)NK
New Zealand (NZ) Vascular Genetics Study AAA GWAS dataset
The Vascular Research Consortium of New Zealand recruited New Zealand men and women with a proven history of AAA infra renal aortic diameter mm proven on u l t r a s o u n d o r C T s c a n A p p r o x i m a t e l y h a d u n d e r g o n e s u r g i c al AAA repair typically AAA s mm in diameter The vast majority of cases were of Anglo European ancestry The control group underwent an abdominal ultrasound scan American Medical Association All rights reserved to exclude mm concurrent AAA and Anglo European ancestry was required for inclusion Controls were also screened for peripheral artery disease PAD using ankle brachial index carotid artery disease ultrasound and other cardiovascular risk factors Two separate GWAS were performed using New Zealand samples NZ GWAS consisted of AAA patients male and elderly controls male genotyped using the Affymetrix SNP GeneChip array All samples had call rates mean NZ GWAS consisted of AAA patients male and elderly controls male genotyped using the )llumina )nfinium Omni BeadChip array All samples had call rates mean All NZ genomic DNA samples exceeded manufacturers quality and quantity requirements having undergone pre assessment by Nanophotometer )mplen Gmb( M"nchen Germany and agarose gel electrophoresis )mputation was conducted separately on NZ GWAS and data sets using the same methods as used for the AC datasets )MPUTE was run on the BC)SNPmax database platform version BC) Platforms Espoo Finland The reference haplotypes were based on the Genomes June release )mputed calls were filtered by quality score excluding those to restrict to higher quality imputed SNPs The genomic inflation factors were and respectively MAF Both NZ GWAS and data sets underwent QC filtering excluding SNPs with call rates a
n d t h o s e t h a t d e m o n s t r a t e d s i g n i f i c a n t d e v i a t i o n f r o m ( a r dy Weinberg equilibrium in the control group P x
Duplicate samples and those that failed genotyping sample call rate were also excluded from further analysis
US (PA) GWAS dataset
AAA patients were enrolled through the Department of Vascular Surgery at Geisinger Medical Center Danville Pennsylvania USA as previously reported To identify cases and controls from the electronic medical records an ePhenotypin g a l g o r i t h m w a s d e v e l o p e d B r i e f l y S t r u c t u r e d Q u e r y L a n g u a g e S Q L w a s u s e d t o s c r i p t t h e algorithm utilizing Current Procedural Terminology CPT and )nternational Classification of Diseases )CD codes as well as demographic and encounter data to classify individuals as case control or excluded AAA cases were defined as having an AAA repair procedure case Type or at least one appropriate specialty encounter vascular clinic with a ruptured AAA case Type or at least two specialty encounters with an unruptured AAA case Type Controls were neither cases nor those excluded had an encounter within the past years and had never been assigned an )CD code of where is a or digit code )ndividuals were excluded if they had a thoracic aortic aneurysm or a rare heritable disease with aortic manifestation they were younger than or older than years they had a single encounter with a code without mention of rupture or they had not had an encounter within the past years Rare heritable diseases were excluded because the goal of the current study was to identify non syndromic AAA Controls under years might yet manifest an AAA while cases under years of age and without rare syndromic forms of aortic aneurysms are likely due to trauma The AAA algorithm can be downloaded from www PheKb org The algorithm was validated on a subset of individuals by manual chart review and implemented at eMERGE network sites The algorithm was implemented as a workflow in the Konstanz )nformation Miner KN)ME http www knime org American Medical Association All rights reserved AAA cases had infrarenal aortic diameter mm as revealed by abdominal imaging Approximately of individuals with AAA had a family history of AAA A control group was obtained through the Geisinger MyCode Project a cohort of Geisinger Clinic patients recruited for genomic studies The MyCode controls were matched for age distribution and sex to the Geisinger Vascular Clinic AAA cases Based on electronic medical records controls had no )CD codes for AAA in their records but they were not screened by ultrasonography for AAA Both cases and controls from the Geisinger Clinic were of European descent
The GWAS data used for this study was a subset of a larger cohort comprising samples from individuals with three phenotypes putative AAA cases obesity cases and controls Samples were genotyped on the ) l l u m i n a (umanOmniExpress v genotyping platform at the University of Pittsburgh Genomics and Proteomics Core Laboratories Genotypes were called using the )llumina GenomeStudio v software QC consisted of a number of steps identification of cross contamination and removal of specimens call rate of samples SNPs called sex consistency between annotated sex and genotyped sex SNP discordance between replicate sample pairs SNP call rate calls in all specimens SNP minor allele frequency SNP (ardy Weinberg equilibrium P x and selection of replicates to retain based on sex specific Mahalanobis distance and )llumina P GC Cross contamination of samples was detected by excess heterozygosity and excess relatedness related to more than half of other samples at Pi hat four samples were removed prior to other QC steps After the QC steps above related individuals pairwise Pi hat were removed retaining the individual and specimen with the highest call rate A second round of QC applied using the above SNP and sample criteria to ensure consistency after removal of SNPs and individuals )n addition the SNP criteria were analyzed per chromosome to ensure that there were n o s y s t e m a t i c differences no differences detected Lastly principle component analysis PCA was used to determine if there were any batch effects during genotyping no evidence for batch effects Of the samples were removed for one or more of the QC reasons above Of the SNPs were removed were discordant had a low call rate had a MAF and had a (WE P x SNPs were removed for more than one reason
The final meta analysis cohort comprised only those individuals who were identified as definitive AAA cases or controls using the rigorous ePhenotyping algorithm described above )mputation was performed as previously described Briefly SNPs were re mapped to the Genome Reference Consortium (uman build GRCh and the program liftOver run to ensure mapping consistency Subsequently all SNPs were mapped from the )llumina TOP notation to the plus strand Strand was checked using S(APE)T version r Next the data were phased using S(APE)T )mputation was performed using )MPUTE version Chromosomes were divided into MB segments with kbp overlap between segments A total of SNPs with an info score of were used for analysis Association analysis without adjustment was performed using PL)NK v and the imputed SNPs The eMERGE Network )mputed GWAS for Phenotypes the dbGaP eMERGE Phase and Merged data Submission accession number is phs v p which includes these AAA data American Medical Association All rights reserved Iceland, deCODE Genetics AAA GWAS dataset )celandic individuals with AAA defined as infra renal aortic diameter mm were recruited from a registry of individuals who were admitted at Landspitali University (ospital in Reykjavik )celand AAA patients were either followed up or treated by intervention for emergency repair of symptomatic or ruptured AAA or for an elective repair by surgery or endovascular intervention )n total whole genome data from subjects with AAA enrolled as part of the cardiovascular disease CVD genetics program at deCODE were included in the metaGWAS The )celandic controls used were selected from individuals who have participated in various GWA studies and who were recruited as part of genetic programs at deCODE )ndividuals with known CVD were excluded as controls but controls were unscreened for AAA The )celandic case and control samples were assayed with the )llumina (uman(ap (uman(apCNV or (uman(ap bead chips )llumina San Diego CA USA Only SNPs present on all chips were included in the analysis and SNPs were excluded if they had a call rates in cases or controls b MAF in the controls or c showed significant deviation from (ardy Weinberg equilibrium in the controls P x These criteria were applied separately to genotype data from each of the chip types used and SNPs that showed significant deviation P x in an ANOVA test in frequency between the chips were excluded from the analysis Any samples with a call rate were excluded from the analysis The final analysis included SNPs present on all three chips
For case control association analysis we used a standard likelihood ratio statistic implemented in the NEMO software to calculate two sided P values and ORs for each individual allele assuming a multiplicative model for risk
The Netherlands AAA GWAS dataset
The AAA sample set from Utrecht was recruited in from centres in The Netherlands mainly when individuals visited their vascular surgeon in the clinic or in rare cases during hospital admission for elective or emergency AAA surgery An AAA was defined as an infrarenal aorta mm The sample set comprised males with a mean AAA diameter of mm had been operated on of which were after rupture The Dutch controls used in the AAA GWAS were recruited as part of the Nijmegen Biomedical Study and the Nijmegen Bladder Cancer Study see http dceg cancer gov icbc membership html Genotyping was performed on )llumina (uman(ap chips As controls we included Dutch subjects who were recruited as part of the Nijmegen Biomedical Study n and the Nijmegen Bladder Cancer Study n These controls were genotyped on )llumina CNV Duo BeadChips
We performed QC using PL)NK version After removal of SNPs with A T or C G alleles and SNPs that were not called in any individual we performed sample QC and SNP QC Sample QC was performed after merging cases and controls using a subset of common high quality SNPs as defined by SNPs without deviation from (ardy Weinberg equilibrium P with high MAF and with low rate of missing genotypes Linkage disequilibrium LD pruning r was performed Subjects were removed based on the following three criteria missing genotypes subjects with call American Medical Association All rights reserved rates were removed heterozygosity subjects were excluded if the inbreeding coefficient deviated more than standard deviations from the mean and cryptic relatedness by calculating identity by descent )BD for each pair of individuals )n each pair with an )BD proportion of a subject was excluded if it exhibited distant relatedness with more than one individual For case control pairs we removed the control subject )n the case case or control control pairs the subject with the lowest call rate was excluded Using these common high quality SNPs we performed PCA using E)GENSTRAT on the remaining study subjects and (apMap CEU subjects We excluded SNPs from three regions with known long distance LD the major histocompatibility M(C region chr Mbp the chromosome inversion chr Mbp and a chromosome region chr Mbp We created PC plots with the first four PCs using R version Based on visual inspection of these plots we excluded subjects that appeared to be outliers with respect to the CEU or the study population After outlier removal we recomputed PCs for them to be included as covariates in the logistic regression models After sample QC we excluded SNPs with more than missing genotypes MAF missing genotype rate higher than MAF and (WE deviation P Because cases and controls had been genotyped separately we performed these QC steps in each study cohort separately and again after merging cases and controls We also removed SNPs with a differential degree of missing genotypes between cases and controls P x chi squared test
We performed genotype imputation u s i n g t h e p r e p h a s i n g i m p u t a t i on stepwise approach implemented in )MPUTE and S(APE)T chunk size of Mb and default parameters
The imputation reference set consisted of phased haplotypes from the full Genomes Project data set February variants All genomic locations are given in NCB) Build UCSC hg coordinates After imputation SNPs with an imputation accuracy score or MAF were excluded
Association testing was carried out in PL)NK using imputed SNP dosages We included as covariates the first four PCs We calculated genomic inflation factors GC defined as the ratio of the median of the empirically observed distribution of the test statistic to the expected median
SMART study
The Secondary Manifestations of ARTerial disease SMART study is a prospective outpatient cohort study among patients aged years newly referred to the University Medical Center Utrecht The Netherlands because of atherosclerotic vascular disease or for treatment of atherosclerotic risk factors The objective of SMART is to determine the prevalence of concomitant asymptomatic arterial disease and risk factors in patients presenting with a manifestation of arterial disease or risk factor and to study the incidence of future cardiovascular events and their predictors in these high risk patients Details of the protocol have been described elsewhere DNA for wet lab genotyping to replicate discovery results of the current study was available in a total of SMART participants There are incident and prevalent AAA cases defined as an infra renal aortic diameter cm and controls included in the analyses There were prevalent AAA end points seen during follow AAA endpoints included death open surgical repair and or endovascular stenting
